Lasofoxifene Improves Vaginal Atrophy in Phase III Trial

Article

Phase II studies have shown that lasofoxifene, a next-generation selective estrogen-receptor modulator, increased bone mineral density and improved both objective measures of vaginal atrophy and reported symptoms. Margery Gass, MD, and a team from the University of Cincinnati Medical Center reported yesterday that a double-blind, randomized, placebo-controlled Phase III trial produced similar results.

Phase II studies have shown that lasofoxifene, a next-generation selective estrogen-receptor modulator, increased bone mineral density and improved both objective measures of vaginal atrophy and reported symptoms. Margery Gass, MD, and a team from the University of Cincinnati Medical Center reported yesterday that a double-blind, randomized, placebo-controlled Phase III trial produced similar results.

A group of 445 postmenopausal women with symptomatic vaginal atrophy (VA) were randomly assigned to receive lasofoxifene (0.25 mg/day or 0.5 mg/day) or placebo. Clinical effect was assessed using vaginal pH and vaginal cytology to determine the maturation index (superficial, intermediate, and parabasal cells). At screening, women were required to have no more than 5% superficial cells and vaginal pH of more than 5.

The results were clear, Dr. Gass said. By week 12, there were adjusted mean decreases in parabasal cells of 38% for the lasofoxifene 0.25 group, 37% for the lasofoxifene 0.5 group, and 3% for the placebo group (P

Gass M, Kagan R, Simon J, Spino C, Barcomb L. Objective measures of vaginal atrophy are improved with lasofoxifene, a next-generation selective estrogen receptor modulator. Obstet Gynecol. 2005;105(4 suppl):71S.

Newsletter

Get the latest clinical updates, case studies, and expert commentary in obstetric and gynecologic care. Sign up now to stay informed.

Recent Videos
Natalia Llarena, MD, discusses rising fertility anxiety in Gen Z | Image Credit: havingbabies.com.
Uma Mahadevan, MD, highlights new guidelines for managing IBD | Image Credit: ucsfhealth.org.
Brittany Ranchoff, PhD, MPH, highlights limited labor after cesarean access | Image Credit: linkedin.com
© 2025 MJH Life Sciences

All rights reserved.